US 10444237
Anti-pancreatic cancer monoclonal antibody and use thereof
granted A61PA61P35/00
Quick answer
US patent 10444237 (Anti-pancreatic cancer monoclonal antibody and use thereof) held by NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD. expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.
- Grant date
- Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61P, A61P35/00